세계의 당뇨병성 신경병증성 통증 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 신경장애 유형별, 약제 클래스별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Diabetic Neuropathic Pain Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Neuropathy Type, Drug Class, By Distribution Channel By Region & Competition, 2020-2030F

US $ 4,500 ￦ 6,279,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,674,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,163,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

당뇨병성 신경병증성 통증 세계 시장 규모는 2024년 16억 4,000만 달러에 달했고, 예측 기간 동안 5.68%의 연평균 복합 성장률(CAGR)로 괄목할 만한 성장을 이룰 것으로 예상됩니다.

세계 당뇨병성 신경병증성 통증 시장은 광범위한 헬스케어 산업에서 역동적이고 빠르게 발전하고 있는 분야로, 전 세계 당뇨병 유병률 증가가 특징입니다. 예를 들어, 2022년 국제당뇨병연맹은 20세에서 79세 사이의 성인 중 약 5억 3,700만 명이 당뇨병을 앓고 있으며, 이는 전 세계 인구 10명 중 1명이 당뇨병을 앓고 있는 것으로 보고하고 있으며, 이는 전 세계적으로 당뇨병에 대한 부담이 증가하고 있음을 보여줍니다. 당뇨병성 신경병증성 통증은 당뇨병 환자의 상당수가 앓고 있는 당뇨병의 고통스럽고 쇠약하게 만드는 합병증입니다. 이 시장에는 당뇨병성 신경병증 환자가 겪는 만성적인 통증과 불편함을 완화하기 위한 다양한 의약품, 의료기기, 치료 중재 등이 포함됩니다. 당뇨병성 신경병증성 통증 세계 시장의 성장을 가속하는 주요 요인으로는 신흥국을 중심으로 한 당뇨병 유병률 증가, 세계 인구의 고령화 등을 들 수 있습니다. 당뇨병이 지속적으로 증가함에 따라 신경병증성 통증으로 이어지는 당뇨병성 신경병증의 유병률도 증가하고 있습니다. 이에 따라 효과적인 통증 관리 솔루션에 대한 수요가 증가하면서 시장의 기술 혁신이 진행되고 있습니다. 예를 들어, CDC에 따르면 미국 인구의 10.5%에 해당하는 약 3,420만 명이 당뇨병을 앓고 있으며, 이는 진단된 경우와 진단되지 않은 경우를 모두 포함합니다. 당뇨병 진단을 받지 않았거나 예비 당뇨병 환자도 상당수에 달하고, 당뇨병 관리와 예방에 대한 관심이 높아지고 있는 것으로 나타났습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	16억 4,000만 달러
시장 규모 : 2030년	22억 7,000만 달러
CAGR : 2025-2030년	5.68%
급성장 부문	말초신경장애
최대 시장	북미

시장 성장 촉진요인

당뇨병 유행 확대

주요 시장 이슈

치료 저항성

주요 시장 동향

환자 중심의 의료

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 당뇨병성 신경병증성 통증 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 신경장애 유형별(말초신경장애, 자율신경장애, 근위신경장애, 국소신경장애)
  • 약제 클래스별(항우울제, 항경련제, 진통제)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 신경장애 유형별
  • 약제 클래스별
  • 유통 채널별
  • 지역별

제5장 아시아태평양의 당뇨병성 신경병증성 통증 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 신경장애 유형별
  • 약제 클래스별
  • 유통 채널별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 당뇨병성 신경병증성 통증 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 당뇨병성 신경병증성 통증 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제8장 남미의 당뇨병성 신경병증성 통증 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 당뇨병성 신경병증성 통증 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 이집트

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제12장 세계의 당뇨병성 신경병증성 통증 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Eli Lilly and Company
• Grunenthal GmBH
• Collegium Pharmaceutical, Inc.
• Lupin Ltd
• Daiichi Sankyo Inc.
• Azurity Pharmaceuticals, Inc.
• Novartis AG
• Pfizer, Inc.
• Endo International plc.(Par Pharmaceutical)
• Johnson & Johnson

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Diabetic Neuropathic Pain Market was valued at USD 1.64 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.68% through 2030. The Global Diabetic Neuropathic Pain Market is a dynamic and rapidly evolving sector within the broader healthcare industry, characterized by a growing prevalence of diabetes worldwide. For instance, in 2022, the International Diabetes Federation reported that approximately 537 million adults aged 20 to 79 had diabetes, affecting 1 in 10 individuals worldwide, highlighting the growing global burden of the disease. Diabetic neuropathic pain is a distressing and debilitating complication of diabetes mellitus, affecting a significant proportion of diabetic patients. This market encompasses a wide range of pharmaceuticals, medical devices, and therapeutic interventions aimed at alleviating the chronic pain and discomfort experienced by individuals with diabetic neuropathy.Key factors driving the growth of the Global Diabetic Neuropathic Pain Market include the escalating incidence of diabetes, particularly in emerging economies, as well as the aging global population. As diabetes continues to rise, so does the prevalence of diabetic neuropathy, which often leads to neuropathic pain. This, in turn, fuels the demand for effective pain management solutions and drives innovation in the market. For instance, according to the CDC, around 34.2 million people in the U.S., or 10.5% of the population, have diabetes, including both diagnosed and undiagnosed cases. A substantial number remain undiagnosed or have prediabetes, highlighting the growing concern of diabetes management and prevention.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.64 Billion
Market Size 2030	USD 2.27 Billion
CAGR 2025-2030	5.68%
Fastest Growing Segment	Peripheral Neuropathy
Largest Market	North America

Key Market Drivers

Escalating Diabetes Epidemic

The escalating diabetes epidemic is undeniably one of the most potent drivers behind the growth of the Global Diabetic Neuropathic Pain Market. Diabetes has reached pandemic proportions, affecting millions of individuals worldwide, and its prevalence continues to surge at an alarming rate.This unprecedented rise in diabetes cases translates directly into a larger pool of individuals at risk of developing diabetic neuropathy, a debilitating complication that frequently leads to neuropathic pain. According to the Ministry of Health and Family Welfare, in collaboration with the WHO Country Office for India and other partners, launched mDiabetes, a mobile health initiative to raise awareness about early diabetes diagnosis and treatment. Similarly, WHO and IDF are working globally to prevent and control diabetes. The WHO Diabetes Program focuses on preventing type 2 diabetes, minimizing complications, and enhancing the quality of life for individuals with diabetes, reinforcing global efforts to improve diabetes care and management.

Key Market Challenges

Treatment Resistance

One of the primary reasons behind treatment resistance is the heterogeneous nature of diabetic neuropathic pain. The condition varies in terms of severity, duration, and underlying mechanisms among individuals. As a result, what works effectively for one patient may not provide the same level of relief for another. This variability underscores the need for personalized treatment approaches tailored to the specific characteristics of each patient's neuropathic pain.

Another contributing factor to treatment resistance is the limited efficacy of current pharmaceutical therapies. While these medications can provide relief for some patients, a significant portion of individuals with diabetic neuropathic pain continues to experience chronic and often debilitating discomfort. This treatment gap highlights the urgent need for more effective and targeted treatment options that can address the multifaceted nature of neuropathic pain.

Key Market Trends

Patient-Centered Care

Patient-centered care is a pivotal trend that is significantly boosting the Global Diabetic Neuropathic Pain Market. In the past, healthcare decisions often followed a one-size-fits-all approach, but the recognition of the unique needs and preferences of individual patients has led to a paradigm shift in the management of diabetic neuropathic pain. This patient-centric approach places the patient at the center of their care, involving them actively in decision-making processes, and tailoring treatment strategies to meet their specific needs.

Key Market Players

Eli Lilly and Company

Grunenthal GmBH

Collegium Pharmaceutical, Inc.

Lupin Ltd

Daiichi Sankyo Inc.

Azurity Pharmaceuticals, Inc.

Novartis AG

Pfizer, Inc.

Endo International plc. (Par Pharmaceutical)

Johnson & Johnson

Report Scope:

In this report, the Global Diabetic Neuropathic Pain Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Neuropathic Pain Market, By Neuropathy Type:

• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

Diabetic Neuropathic Pain Market, By Drug Class:

• Antidepressants
• Anticonvulsants
• Analgesics

Diabetic Neuropathic Pain Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Diabetic Neuropathic Pain Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Neuropathic Pain Market.

Available Customizations:

Global Diabetic Neuropathic Pain Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Diabetic Neuropathic Pain Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Neuropathy Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy)
  • 4.2.2. By Drug Class (Antidepressants, Anticonvulsants, Analgesics)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Neuropathy Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Diabetic Neuropathic Pain Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Neuropathy Type
  • 5.2.2. By Drug Class
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Diabetic Neuropathic Pain Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Neuropathy Type
      • 5.3.1.2.2. By Drug Class
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Diabetic Neuropathic Pain Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Neuropathy Type
      • 5.3.2.2.2. By Drug Class
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Diabetic Neuropathic Pain Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Neuropathy Type
      • 5.3.3.2.2. By Drug Class
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Diabetic Neuropathic Pain Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Neuropathy Type
      • 5.3.4.2.2. By Drug Class
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Diabetic Neuropathic Pain Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Neuropathy Type
      • 5.3.5.2.2. By Drug Class
      • 5.3.5.2.3. By Distribution Channel

6. Europe Diabetic Neuropathic Pain Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Neuropathy Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Diabetic Neuropathic Pain Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Neuropathy Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Diabetic Neuropathic Pain Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Neuropathy Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Diabetic Neuropathic Pain Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Neuropathy Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Diabetic Neuropathic Pain Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Neuropathy Type
      • 6.3.4.2.2. By Drug Class
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Diabetic Neuropathic Pain Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Neuropathy Type
      • 6.3.5.2.2. By Drug Class
      • 6.3.5.2.3. By Distribution Channel

7. North America Diabetic Neuropathic Pain Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Neuropathy Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Diabetic Neuropathic Pain Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Neuropathy Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Diabetic Neuropathic Pain Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Neuropathy Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Diabetic Neuropathic Pain Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Neuropathy Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Distribution Channel

8. South America Diabetic Neuropathic Pain Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Neuropathy Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Diabetic Neuropathic Pain Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Neuropathy Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Diabetic Neuropathic Pain Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Neuropathy Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Diabetic Neuropathic Pain Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Neuropathy Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Diabetic Neuropathic Pain Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Neuropathy Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Diabetic Neuropathic Pain Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Neuropathy Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Diabetic Neuropathic Pain Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Neuropathy Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Diabetic Neuropathic Pain Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Neuropathy Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Distribution Channel
  • 9.3.4. Egypt Diabetic Neuropathic Pain Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Neuropathy Type
      • 9.3.4.2.2. By Drug Class
      • 9.3.4.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Diabetic Neuropathic Pain Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Eli Lilly and Company
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Grunenthal GmBH
• 14.3. Collegium Pharmaceutical, Inc.
• 14.4. Lupin Ltd
• 14.5. Daiichi Sankyo Inc.
• 14.6. Azurity Pharmaceuticals, Inc.
• 14.7. Novartis AG
• 14.8. Pfizer, Inc.
• 14.9. Endo International plc. (Par Pharmaceutical)
• 14.10.Johnson & Johnson

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료